News

Myeloma UK study of patient preferences published

Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…

Details

Phase III carfilzomib trial meets primary endpoint

Amgen has announced that its Phase III trial, ARROW, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared the effect of giving patients a higher dose of carfilzomib (Kyprolis®) once a week, compared to a smaller dose twice a week, together with dexamethasone. The…

Details

MUK nine opens for recruitment

Myeloma UK is pleased to announce that MUK nine is the latest trial in the Myeloma UK Clinical Trial Network (CTN) open to patient recruitment. The aim of MUK nine is to stratify treatment for high-risk myeloma patients. Up to 700 newly diagnosed myeloma patients will be recruited and screened at the Institute of Cancer…

Details

SMC approves restricted use of daratumumab monotherapy for relapsed and refractory myeloma

The Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex®) monotherapy as a fourth line treatment option for relapsed and refractory myeloma patients in Scotland, who have previously received treatment with a proteasome inhibitor and immunomodulatory drug. This decision is based on the pooled analysis of results from two clinical trials, MMY2002 and…

Details

FDA accepts new drug application for carfilzomib monotherapy as a treatment for relapsed or refractory myeloma

The U.S. pharmaceutical company, Onyx, has announced that the U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) for the use of carfilzomib (Kyprolis®) monotherapy as a treatment for relapsed and/or refractory myeloma patients. The application was based upon the results from the 003-A1 trial which demonstrated patients responded well to…

Details

FDA place clinical hold on all checkpoint inhibitor combination trials for myeloma patients

The U.S. Food and Drug Administration (FDA) has placed clinical holds on all trials investigating checkpoint inhibitors in combination with immunomodulatory (IMiD) drugs for the treatment of myeloma patients. This decision follows the recent suspension of clinical trials investigating pembrolizumab (Keytruda®) in combination with IMiD drugs as a treatment for myeloma patients, after higher death…

Details